Compare Novartis AG (NVS) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Solaredge Technologies Inc — how do they compare? Novartis AG trades at $139.7 (market cap $262.28B), while Solaredge Technologies Inc trades at $35.12 (market cap $2.17B). The key difference: Novartis AG is far larger — about 120.9× Solaredge Technologies Inc's market cap, and Novartis AG pays a 3.45% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| NVS | SEDG | |
|---|---|---|
Market Cap | $262.28B | $2.17B |
Sector | Health | Technology |
52-Week High | $168.62 | $78.51 |
52-Week Low | $121.80 | $28.47 |
Enterprise Value | $303.60B | $2.03B |
Dividend Yield | 3.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
SolarEdge (SEDG) trades at $36.43, up 6.52% today, with a bullish technical signal despite negative profitability. Revenue declined to $1.18B in 2025, with a net loss of $405M, though recent quarterly EPS beat expectations. The stock shows improved cash flow from operations at $104M in 2025, and news highlights collaboration with Infineon for AI data center technology, driving positive sentiment.
Outlook remains cautious due to persistent losses and high debt, but analyst consensus price target of $41 offers 12.5% upside. Key risks include reliance on policy incentives and competitive pressures. Institutional sentiment is mixed with 23% buy ratings, suggesting patience for margin recovery and AI-related growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
